Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946938 | 1.00 | GRB2 (0.49) | GRB2F2DPP4FAPDPP8 | |
| SCHEMBL4946515 | 0.94 | GRB2 (0.47) | GRB2CXCL8CAPN1 | |
| SCHEMBL4946505 | 0.94 | GRB2 (0.47) | GRB2CXCL8CAPN1 | |
| SCHEMBL30830432 | 0.88 | FNTA (0.44) | GRB2FNTAFNTBXIAP | |
| SCHEMBL30787962 | 0.87 | GRB2 (0.45) | GRB2CXCL8CAPN1OPRM1 | |
| SCHEMBL30052397 | 0.86 | XIAP (0.48) | GRB2F2FNTAFNTBOPRM1 | |
| SCHEMBL30185040 | 0.85 | GRB2 (0.45) | GRB2F2FNTAFNTBOPRM1 | |
| SCHEMBL30591055 | 0.85 | GRB2 (0.45) | GRB2F2FNTAFNTBOPRM1 | |
| SCHEMBL29641611 | 0.85 | DPP4 (0.55) | GRB2F2DPP4FAPDPP8 | |
| SCHEMBL29630429 | 0.84 | GRB2 (0.47) | GRB2F2FNTAFNTBOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470776-B2 | Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070167356-A1 | Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof | CUMMINGS RICHARD D | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167356-A1 | Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof | SIGLEC7, SIGLEC9, SELL | GRB2 321/4885F2 662/4885DPP4 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.